Griffiths Robert I, Newsome Britt B, Block Geoffrey A, Herbert Robert J, Danese Mark D
Department of Epidemiology, Outcomes Insights, Inc., Westlake Village, CA 91362, USA.
Int J Nephrol. 2011;2011:891259. doi: 10.4061/2011/891259. Epub 2011 Dec 8.
Blood flow rate (BFR) <300 mL/min commonly is used to define hemodialysis catheter dysfunction and the need for interventions to prevent complications. The objective of this study was to describe patterns of unplanned BFR <300 mL/min during catheter hemodialysis using data from DaVita dialysis facilities and the United States Renal Data System. Patients were included if they received at least eight weeks of hemodialysis exclusively through a catheter between 08/04 and 12/06, and catheter hemodialysis was the first treatment modality following diagnosis of end-stage renal disease (first access), or it immediately followed at least one 30-day period of dialysis exclusively through a fistula or graft (replacement access). Actual BFR <300 mL/min despite a planned BFR ≥300 mL/min defined catheter dysfunction during each dialysis session. There were 3,364 patients, 268,363 catheter dialysis sessions, and 19,118 (7.1%) sessions with catheter dysfunction. Almost two-thirds of patients had ≥1 catheter dysfunction session, and 30% had ≥1 catheter dysfunction session per month. Patients with catheter as a replacement access had a higher rate of catheter dysfunction than those with a catheter as first access (hazard ratio: 1.13; P = 0.04). Catheter dysfunction affects almost one-third of catheter dialysis patients each month and two-thirds overall.
血流量(BFR)<300毫升/分钟通常用于定义血液透析导管功能障碍以及采取干预措施预防并发症的必要性。本研究的目的是利用达维塔透析机构和美国肾脏数据系统的数据,描述导管血液透析期间计划外BFR<300毫升/分钟的模式。如果患者在08/04至12/06期间仅通过导管接受了至少八周的血液透析,且导管血液透析是终末期肾病诊断后的第一种治疗方式(首次通路),或者在至少一个为期30天的仅通过内瘘或移植物进行透析的时期之后立即进行(替代通路),则纳入研究。尽管计划BFR≥300毫升/分钟,但实际BFR<300毫升/分钟定义为每次透析期间的导管功能障碍。共有3364例患者,268363次导管透析治疗,其中19118次(7.1%)存在导管功能障碍。近三分之二的患者有≥1次导管功能障碍治疗,30%的患者每月有≥1次导管功能障碍治疗。作为替代通路的导管患者比作为首次通路的导管患者有更高的导管功能障碍发生率(风险比:1.13;P=0.04)。导管功能障碍每月影响近三分之一的导管透析患者,总体上影响三分之二的患者。